Samuel J Reddick1, Olivia Campagne1, Jie Huang2, Arzu Onar-Thomas2, Alberto Broniscer3, Amar Gajjar3, Clinton F Stewart4. 1. Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA. 2. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA. 3. Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 4. Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA. clinton.stewart@stjude.org.
Abstract
PURPOSE: Erlotinib (Tarceva®), a potent small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been evaluated to treat infants and children with primary brain tumors. The pharmacokinetics of erlotinib and its primary metabolite OSI-420 were characterized and exposure-safety associations were investigated. METHODS: This analysis involved patients enrolled in two clinical studies and receiving oral erlotinib once daily as part of treatment. Single-dose and steady-state erlotinib and OSI-420 plasma concentrations were assayed using HPLC-MS/MS methods. Population pharmacokinetic modeling and univariate covariate analysis evaluating demographic, clinical and selected CYP3A5, CYP3A4, ABCB1, and ABCG2 genotypes were performed. Associations between erlotinib and OSI-420 pharmacokinetics, and with toxicities (diarrhea and skin rash) occurring post-dose were explored. RESULTS: Data from 47 patients (0.7-19 years old) were collected and best fitted by one-compartment linear models. Erlotinib and OSI-420 apparent clearances (CL/F and CLm/Fm) were higher in patients < 5 years compared to older patients (mean CL/F: 6.8 vs 3.6 L/h/m2, and mean CLm/Fm: 79 vs 38 L/h/m2, p < 0.001), and were 1.62-fold and 1.73-fold higher in males compared to females (p < 0.01). Moreover, CL/F was 1.53-fold higher in wild-type patients than in patients heterozygous or homozygous mutant for ABCG2 rs55930652 (p < 0.05). Most of the toxicities reported were grade 1. No associations were found between drug pharmacokinetics and drug-induced toxicities. CONCLUSIONS: Erlotinib therapy was well tolerated by pediatric patients with primary brain tumors. No dosing adjustments based on age or patient characteristics are recommended for this patient population.
PURPOSE:Erlotinib (Tarceva®), a potent small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been evaluated to treat infants and children with primary brain tumors. The pharmacokinetics of erlotinib and its primary metabolite OSI-420 were characterized and exposure-safety associations were investigated. METHODS: This analysis involved patients enrolled in two clinical studies and receiving oral erlotinib once daily as part of treatment. Single-dose and steady-state erlotinib and OSI-420 plasma concentrations were assayed using HPLC-MS/MS methods. Population pharmacokinetic modeling and univariate covariate analysis evaluating demographic, clinical and selected CYP3A5, CYP3A4, ABCB1, and ABCG2 genotypes were performed. Associations between erlotinib and OSI-420 pharmacokinetics, and with toxicities (diarrhea and skin rash) occurring post-dose were explored. RESULTS: Data from 47 patients (0.7-19 years old) were collected and best fitted by one-compartment linear models. Erlotinib and OSI-420 apparent clearances (CL/F and CLm/Fm) were higher in patients < 5 years compared to older patients (mean CL/F: 6.8 vs 3.6 L/h/m2, and mean CLm/Fm: 79 vs 38 L/h/m2, p < 0.001), and were 1.62-fold and 1.73-fold higher in males compared to females (p < 0.01). Moreover, CL/F was 1.53-fold higher in wild-type patients than in patients heterozygous or homozygous mutant for ABCG2rs55930652 (p < 0.05). Most of the toxicities reported were grade 1. No associations were found between drug pharmacokinetics and drug-induced toxicities. CONCLUSIONS:Erlotinib therapy was well tolerated by pediatric patients with primary brain tumors. No dosing adjustments based on age or patient characteristics are recommended for this patient population.
Authors: Sunil Krishnan; Paul D Brown; Karla V Ballman; John B Fiveash; Joon H Uhm; Caterina Giannini; Kurt A Jaeckle; Francois J Geoffroy; L Burt Nabors; Jan C Buckner Journal: Int J Radiat Oncol Biol Phys Date: 2006-04-19 Impact factor: 7.038
Authors: Jeffrey J Raizer; Lauren E Abrey; Andrew B Lassman; Susan M Chang; Kathleen R Lamborn; John G Kuhn; W K Alfred Yung; Mark R Gilbert; Kenneth A Aldape; Patrick Y Wen; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Frank Lieberman; Timothy F Cloughesy; H Ian Robins; Janet Dancey; Michael D Prados Journal: Neuro Oncol Date: 2009-12-14 Impact factor: 12.300
Authors: Michael D Prados; Kathleen R Lamborn; Susan Chang; Eric Burton; Nicholas Butowski; Mary Malec; Ami Kapadia; Jane Rabbitt; Margaretta S Page; Ann Fedoroff; Dong Xie; Sean K Kelley Journal: Neuro Oncol Date: 2006-01 Impact factor: 12.300
Authors: Alberto Broniscer; John C Panetta; Melinda O'Shaughnessy; Charles Fraga; Feng Bai; Matthew J Krasin; Amar Gajjar; Clinton F Stewart Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531
Authors: Bret Wacker; Tina Nagrani; Jacqueline Weinberg; Karsten Witt; Gary Clark; Pablo J Cagnoni Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531
Authors: Anil R Maharaj; Daniel Gonzalez; Michael Cohen-Wolkowiez; Christoph P Hornik; Andrea N Edginton Journal: Clin Pharmacokinet Date: 2018-05 Impact factor: 5.577